Gavin MacBeath, Ph.D.

Gavin MacBeath, Ph.D.

Chief Executive Officer and DirectoratTScan Therapeutics· In proxies 2022–2025

Pay in FY2025TScan Therapeutics stock -67.1% the same year

Gavin MacBeath, Ph.D. was paid $2.8M in FY2025 (Dec). TScan Therapeutics stock fell 67.1% that year.

Pay$100 in the stock at the end of FY21 → $43
Pay is from the Summary Compensation Table of each TScan Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. TScan TherapeuticsPublic company · 4 yr
    • Chief Executive Officer and Director2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?